Spexis AG (XSWX:SPEX) Payments of Debt : CHF-0.28 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Payments of Debt?

Spexis AG's Payments of Debt for the six months ended in Jun. 2023 was CHF-0.16 Mil.

Spexis AG's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-0.28 Mil.

Spexis AG Payments of Debt Historical Data

The historical data trend for Spexis AG's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Payments of Debt Chart

Spexis AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Payments of Debt

Get a 7-Day Free Trial

-0.58

-0.24

-2.40

-0.16

-0.28

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Payments of Debt	Get a 7-Day Free Trial												-	-0.16	-0.16	-0.12	-0.16

Spexis AG Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.28 Mil.

Spexis AG Payments of Debt Related Terms

Thank you for viewing the detailed overview of Spexis AG's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Payments of Debt

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines